Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
27.24
+0.65 (2.44%)
At close: Mar 9, 2026, 4:00 PM EDT
26.40
-0.84 (-3.08%)
After-hours: Mar 9, 2026, 7:45 PM EDT
Mineralys Therapeutics Employees
Mineralys Therapeutics had 51 employees as of December 31, 2024. The number of employees increased by 23 or 82.14% compared to the previous year.
Employees
51
Change (1Y)
23
Growth (1Y)
82.14%
Revenue / Employee
n/a
Profits / Employee
-$3,360,059
Market Cap
2.16B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51 | 23 | 82.14% |
| Dec 31, 2023 | 28 | 16 | 133.33% |
| Dec 31, 2022 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ultragenyx Pharmaceutical | 1,371 |
| Iovance Biotherapeutics | 975 |
| Ascentage Pharma Group International | 605 |
| Galapagos NV | 558 |
| Ocular Therapeutix | 325 |
| Soleno Therapeutics | 182 |
| Day One Biopharmaceuticals | 178 |
MLYS News
- 3 hours ago - Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results - GlobeNewsWire
- 12 hours ago - Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 - GlobeNewsWire
- 11 days ago - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 - GlobeNewsWire
- 3 months ago - Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup - GlobeNewsWire
- 3 months ago - Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 - GlobeNewsWire